To include your compound in the COVID-19 Resource Center, submit it here.

Vertex falls after CF data

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) fell $5.07 (10%) to $48.07 on Thursday after reporting interim Phase II data for a combination of two cystic fibrosis candidates. Although

Read the full 267 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE